Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Apply
ABP 938 vs. Aflibercept
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step